Irma Lapaj
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Irma Lapaj has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Adriatik Berisha
Hematology Unit, University of Pristina, Pristina, Kosovo, University Clinical Center of Kosovo, Pristina, Serbia, Kosovo
1 shared publication - Alma Cili
Hematology Unit, Madre Teresa Hospital, University of Tirana, University of Tirana, Tirana, Albania, Albania
1 shared publication - Blerina Cela
Department of Pathology, Salus Hospital, Tirana, University of Tirana, Tirana, Albania, Albania
1 shared publication - Fisnik Kurshumliu
Faculty of Medicine, University of Prishtina, 10000 Prishtina, Kosovo
1 shared publication - Luigi Cimmino
Biobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy, University of Bologna, Bologna, Italy, Italy
1 shared publication - Martina Lopiano
Biobank of Research, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Bologna University School of Medicine, Bologna, Italy, University of Bologna, Bologna, Italy, Italy
1 shared publication
Latest Publications
- Open Access
- 23 March 2026
- Published by MDPI AG in Preprints.org
The Evolving Genetics of AML: Implications for Practice in Albania and Kosovo
Acute myeloid leukemia (AML) is a genetically diverse clonal illness marked by the accumulation of somatically acquired genetic abnormalities in hematopoietic progenitors, leading to poor differentiation and unchecked proliferation. Over the last twenty years, the amalgamation of traditional cytogenetics, molecular genetics, and, more recently, next-generation sequencing (NGS) has transformed diagnostic procedures, enhanced risk stratification models, and revealed new therapeutic targets that are altering the treatment landscape. Molecular genetic analysis of CEBPA, NPM1, and FLT3 is currently standard of care in AML patients, and mutations in several other genes are becoming more important, including NPM1, TET2, KIT, DNMT3A, IDH1/2, RUNX1, AXSL1, WT1, and RAS. In this article, the authors review the most relevant literature concerning AML genetics and discuss, based on their own experience and expertise, the perspectives on precision medicine in AML, and addresses practical issues faced in low-resource nations like Albania and Kosovo.
- 23 March 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Evolving Genetics of AML: Implications for Practice in Albania and Kosovo
Acute myeloid leukemia (AML) is a genetically diverse clonal illness marked by the accumulation of somatically acquired genetic abnormalities in hematopoietic progenitors, leading to poor differentiation and unchecked proliferation. Over the last twenty years, the amalgamation of traditional cytogenetics, molecular genetics, and, more recently, next-generation sequencing (NGS) has transformed diagnostic procedures, enhanced risk stratification models, and revealed new therapeutic targets that are altering the treatment landscape. Molecular genetic analysis of CEBPA, NPM1, and FLT3 is currently standard of care in AML patients, and mutations in several other genes are becoming more important, including NPM1, TET2, KIT, DNMT3A, IDH1/2, RUNX1, AXSL1, WT1, and RAS. In this article, the authors review the most relevant literature concerning AML genetics and discuss, based on their own experience and expertise, the perspectives on precision medicine in AML, and addresses practical issues faced in low-resource nations like Albania and Kosovo.